top of page

ASCO 2026: Allogene announced a CEO succession plan late last week. The two leaders behind it discuss why now is the right time, and update us on the progress of the company's programs

  • May 31
  • 1 min read

Current CEO David Chang describes why now was the right time to pass the baton to Zach Roberts, and why they are both excited about the company's 1L large B-cell lymphoma program, and learnings on why they believe using a combo approach of CD19 and CD70 is an effective way to go about allogeneic therapy in the future.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page